You are here

Clin Cancer Res DOI:10.1158/1078-0432.CCR-16-2154-T

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Publication TypeJournal Article
Year of Publication2017
AuthorsGibson, WJ, Ruan, DT, Paulson, VA, Barletta, JA, Hanna, GJ, Kraft, S, Calles, A, Nehs, MA, Moore, FD, Taylor-Weiner, A, Wala, JA, Zack, TI, Lee, TC, Fennessy, FM, Alexander, EK, Thomas, T, Jänne, PA, Garraway, LA, Carter, SL, Beroukhim, R, Lorch, JH, Van Allen, EM
JournalClin Cancer Res
Date Published2017 May 01

Purpose: Cancers may resist single-agent targeted therapies when the flux of cellular growth signals is shifted from one pathway to another. Blockade of multiple pathways may be necessary for effective inhibition of tumor growth. We document a case in which a patient with anaplastic thyroid carcinoma (ATC) failed to respond to either mTOR/PI3K or combined RAF/MEK inhibition but experienced a dramatic response when both drug regimens were combined.Experimental Design: Multi-region whole-exome sequencing of five diagnostic and four autopsy tumor biopsies was performed. Meta-analysis of DNA and RNA sequencing studies of ATC was performed.Results: Sequencing revealed truncal BRAF and PIK3CA mutations, which are known to activate the MAPK and PI3K/AKT pathways, respectively. Meta-analysis demonstrated 10.3% cooccurrence of MAPK and PI3K pathway alterations in ATC. These tumors display a separate transcriptional profile from other ATCs, consistent with a novel subgroup of ATC.Conclusions: BRAF and PIK3CA mutations define a distinct subset of ATC. Blockade of the MAPK and PI3K pathways appears necessary for tumor response in this subset of ATC. This identification of synergistic activity between targeted agents may inform clinical trial design in ATC. Clin Cancer Res; 23(9); 2367-73. ©2016 AACR.


Alternate JournalClin. Cancer Res.
PubMed ID27797976
PubMed Central IDPMC5393965